Document Detail

A study of drug utilisation and cost of treatment in patients hospitalised with unstable angina.
MedLine Citation:
PMID:  11214788     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The current study was designed to investigate drug utilisation in the management of unstable angina in India and to calculate the costs incurred by patients in the treatment of a single episode of unstable angina. METHODS: We conducted a prescription survey to examine the use of antianginal drugs in patients with unstable angina in a tertiary care Indian hospital. The use of concurrent medications such as antidiabetic, antihypertensive and lipid-lowering agents was also examined. Data on the cost of treatment, investigations, income, and family size were collected from the case histories or direct interviews with the patients/relatives. RESULTS: A total of 336 consecutive prescriptions were evaluated. Aspirin was the most frequently prescribed drug (98%) followed by nitroglycerin infusion (90%) and enoxaparin (52%). One of the heparins was used by 89% of all patients and beta-blockers by up to 62% of the patients. Besides antianginals, antihypertensive (49%) and antidiabetic (16%) drugs were commonly coadministered. The mean (+/- SD) cost of treatment of a single episode of unstable angina in the hospital was US $494 (+/- 271) against an annual per capita income of US $245. The mean (+/- SD) cost incurred by the patients due to drugs alone during the hospital stay was US $70 (+/- 18) and enoxaparin accounted for 60% of the expenditure due to drugs. CONCLUSIONS: The results of our study show that low-molecular-weight heparin, enoxaparin, is replacing unfractionated heparin in the treatment of unstable angina. In view of the use of costly new drugs, there is an urgent need for carrying out pharmacoeconomic analysis in developing countries as the treatment of a single episode of unstable angina imparts a considerable economic burden on the patient.
S Malhotra; A Grover; N K Verma; V K Bhargava
Related Documents :
7575048 - Drug-related morbidity and mortality. a cost-of-illness model.
6782868 - Drug waste in long-term care facilities: impact of drug distribution system.
4077288 - Drug removal during continuous arteriovenous hemofiltration: theory and clinical observ...
15386658 - Public and private pharmaceutical spending as determinants of health outcomes in canada.
2869578 - Future treatment of peptic ulcers.
19655718 - Biomimetic doxorubicin loaded polymersomes from hyaluronan-block-poly(gamma-benzyl glut...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  56     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2001-02-14     Completed Date:  2001-05-10     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  755-61     Citation Subset:  IM    
Department of Pharmacology, Postgraduate Insitute of Medical Education and Research, Chandigarh, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina, Unstable / drug therapy*,  economics*
Drug Costs
Drug Prescriptions / economics
Drug Utilization / economics*,  statistics & numerical data*
Fibrinolytic Agents / economics,  therapeutic use
Heparin / economics,  therapeutic use
Hospitalization / economics
Nitroglycerin / economics,  therapeutic use
Vasodilator Agents / economics,  therapeutic use
World Health Organization
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Vasodilator Agents; 55-63-0/Nitroglycerin; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influence of physician's education, drug information and medical-care settings on the quality of dru...
Next Document:  Agranulocytosis associated with calcium dobesilate clinical course and risk estimation with the case...